Progyny, Inc. (NASDAQ:PGNY) Receives Average Rating of “Moderate Buy” from Brokerages

Progyny, Inc. (NASDAQ:PGNY) has earned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $27.9091.

Several brokerages have issued reports on PGNY. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Citizens Jmp raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price objective for the company in a report on Tuesday, January 20th. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a research note on Wednesday, January 21st. Citigroup raised Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Finally, Barclays cut their price objective on Progyny from $29.00 to $23.00 and set an “overweight” rating for the company in a report on Friday, March 20th.

Insider Activity at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the sale, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 7,455 shares of company stock worth $129,515 over the last quarter. Company insiders own 9.40% of the company’s stock.

Institutional Trading of Progyny

Several hedge funds have recently added to or reduced their stakes in PGNY. River Road Asset Management LLC grew its stake in shares of Progyny by 13.9% during the fourth quarter. River Road Asset Management LLC now owns 687,824 shares of the company’s stock valued at $17,663,000 after buying an additional 83,912 shares during the last quarter. Invesco Ltd. boosted its holdings in Progyny by 17.2% during the 4th quarter. Invesco Ltd. now owns 466,769 shares of the company’s stock valued at $11,987,000 after acquiring an additional 68,473 shares during the period. Caitlin John LLC grew its position in Progyny by 72.3% during the 4th quarter. Caitlin John LLC now owns 12,796 shares of the company’s stock worth $329,000 after acquiring an additional 5,371 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in Progyny in the 4th quarter worth approximately $275,000. Finally, XTX Topco Ltd bought a new stake in Progyny in the fourth quarter valued at approximately $3,058,000. 94.93% of the stock is owned by institutional investors.

Progyny Stock Performance

NASDAQ:PGNY opened at $17.27 on Monday. Progyny has a 52-week low of $16.75 and a 52-week high of $28.75. The stock has a fifty day moving average of $20.60 and a 200 day moving average of $22.36. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of 26.57, a P/E/G ratio of 1.00 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The firm had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities analysts forecast that Progyny will post 0.6 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.